Objective-Endothelial sphingosine-1-phosphate (S1P) receptor-1 (S1P 1 ) affects different vascular functions, including blood vessel maturation and permeability. Here, we characterized the role of the zS1P 1 ortholog in vascular development in zebrafish. 
T he lysophospholipid sphingosine-1-phosphate (S1P) is a signaling molecule that acts through the binding to a family of 7-transmembrane G-protein-coupled receptors that include 5 high-affinity members (S1P [1] [2] [3] [4] [5] ).
1 S1P receptors modulate a variety of biological processes, including cell adhesion, migration, and endocytosis with different and sometimes opposing effects on the regulation of cellular functions. 2 In particular, endothelial S1P 1 is involved in cytoskeletal rearrangement and formation of intercellular adherens junctions, its exposure to blood-borne S1P being required for the maintenance of blood-barrier integrity in defined vascular beds. 3, 4 Also, genetic deletion demonstrates the nonredundant role of S1P 1 in vascular maturation during embryogenesis, leading to embryonic lethality in knockout mice. 5 Thus, chemical modulators of S1P 1 activity have been developed as putative therapeutic molecules acting to restore endothelial barrier integrity in various pathological conditions characterized by the disruption of endothelial cell-cell interaction in different organs, including lung, heart, kidney, and brain. 4 Endothelial barrier integrity is dependent upon a complex network of molecular interactions involving adherens and tight junctions.
6 S1P may affect endothelial cell-cell junctions by regulating assembly and expression of the major adherens junction component, vascular endothelial adhesion molecule VE-cadherin, and formation of zonula occludens 1 (ZO1) + tight junctions. [7] [8] [9] [10] However, the molecular and functional bases of the impact of the S1P/S1P 1 receptor system on endothelial barrier integrity remain to be fully elucidated.
The teleost zebrafish (Danio rerio) represents a promising experimental model for in vivo analysis of the molecular and cellular mechanisms underlying blood vessel development and vascular dysfunctions. 6 When compared with other vertebrate model systems, zebrafish offers many advantages, including ease of experimentation, drug administration, amenability to in vivo manipulation, and feasibility of reverse and forward genetic approaches. 11 Also, zebrafish possesses a complex circulatory system similar to that of mammals and the optical transparency and ability to survive for several days without a Expression of the zebrafish ortholog of the S1P 1 receptor (zS1P 1 ) has been observed in the zebrafish embryonic brain, 13 whereas zebrafish mutants of the S1P 2 receptor ortholog miles apart (mil) show organogenesis defects of the heart, 14 demonstrating that bioactive lipid receptors play different roles in zebrafish development. In the present work, we performed the characterization and functional analysis of zS1P 1 receptor during vascular development in zebrafish. zS1P 1 is transiently expressed in the axial vasculature of the trunk of zebrafish embryos. zS1P 1 knockdown caused defects of venous vascular integrity, including VE-cadherin downregulation and disorganization of endothelial junctions, lack of blood circulation, and late generalized edema. In association with these defects, zS1P 1 morphants showed the downregulation of the Eph receptor EphB4a in venous axial endothelium. Similar defects were observed in VE-cadherin morphants and genetic evidence indicate that VE-cadherin is a zS1P 1 -regulated element that controls venous endothelial barrier integrity by acting upstream of EphB4a. Finally, S1P 1 small interfering RNA (siRNA) transfection and the specific S1P 1 antagonist W146 15 cause EPHB4 receptor downmodulation in human umbilical vein endothelial cells (HUVECs). Furthermore, a selective EPHB4 antagonist disrupts ZO1 + intercellular contacts in these cells. Together, the results provide evidence for a nonredundant role for S1P 1 in the regulation of blood-barrier integrity via a novel S1P 1 /VE-cadherin/EphB4a cascade that controls venous endothelial cell-cell junction assembly.
Materials and Methods
Reagents S1P, dihydro-S1P (dhS1P), and W146 were from Avanti Polar Lipids Inc (Alabaster, AL). 5-[4-phenyl-5-(trifluoromethyl)-2-thienyl]-3-[3-(trifluoromethyl)phenyl]-1,2,4-oxadiazole (SEW2871) was from Calbiochem (Nottingham, UK). Racemic 2-amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol mono (dihydrogen phosphate) ester (FTY720-P) and [2-(4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl amino) ethanol (CYM-5442) were synthesized as described. 16, 17 TNYL-RAW peptide (YNYLFSPNGPIARAW) and scrambled peptide SCR-WTL (WTLAIFARNYNGPSP) 18, 19 were kindly provided by Dr O. Salvucci (Bethesda, MD).
Zebrafish Stocks
Wild-type AB and transgenic tg(fli1:enhanced green fluorescent protein [EGFP]) y120 zebrafish lines were maintained under standard conditions, 21 and embryos were staged by hours postfertilization (hpf), as described. 22 When specified, fertilized eggs were maintained in fish water containing 250 mmol/L D-mannitol (Sigma, St. Louis, MO) or treated with 0.66 mg/mL tricaine at different developmental stages and allowed to develop at 28.5°C.
Whole-Mount In Situ Hybridization
Digoxigenin-labeled RNA probes were transcribed from linear cDNA constructs (Roche Applied Science, Indianapolis, IN). Whole-mount in situ hybridization (ISH) was performed as described. 23 For sectioning, fixed embryos were dehydrated in ethanol series, cleared in xilol, and paraffin embedded overnight.
Morpholino-Mediated Knockdown of zS1P 1 and VE-cadherin
Antisense morpholino oligonucleotides (MO) (Gene Tools, Corvallis, OR) were directed against the 5ʹ untranslated region spanning the zS1P 1 ATG start codon (zS1P 1 -MO: 5ʹ-AGTGTCTGGCGATTAGGT CATCCAT-3ʹ) or were designed to complement exon-intron boundaries of the zebrafish VE-cadherin gene (VE-cadherin-MO: 5ʹ-TTT ACAAGACCGTCTACCTTTCCAA-3ʹ). Standard MO (Std-MO: 5ʹ-CCTCTTACCTCAGTTACAATTTATA-3ʹ) was used as control. Routinely, MOs were microinjected in 4.0 nL volume into 1-to 4-cell stage embryos at the concentration of 0.4 pmoles/embryo for zS1P 1 -MO or 1.0 pmoles/embryo for VE-cadherin-MO. A subset of embryos was coinjected with 0.25 to 0.4 pmoles/embryo of zS1P 1 -MO and human S1P 1 mRNA (70-100 pg/embryo), murine VE-cadherin mRNA (40-60 pg/embryo), or human VEGF-A mRNA (100 pg/embryo). zS1P 1 -MO shows no significant homology with human S1P 1 mRNA and murine VE-cadherin mRNA sequences.
Microangiography
Tetramethylrhodamine isothiocyanate-dextran (molecular weight 2.0×10 6 ; Invitrogen, Carlsbad, CA) was dissolved in double distilled water at 20 mg/mL and microinjected into the sinus venosus of zebrafish embryos at 50 hpf as described.
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Microscopy
Embryos were mounted in agarose-coated dishes and photographed under an epifluorescence Leica MZ16 F stereomicroscope (1× Plan Apo objective; NA, 0.141) equipped with a DFC480 digital camera and ICM50 software version 2.8.1 (all from Leica, Wetzlar, Germany). Confocal images were acquired with an LSM 50 META confocal laser microscope (Carl Zeiss, Germany). When specified, dechorionated 28 hpf zebrafish embryos were fixed overnight at 4°C with 1.5% glutaraldehyde plus 4% paraformaldehyde in 0.1 mol/L sodium cacodylate buffer, pH 7.3. Then, embryos were postfixed for 1 hour in sodium-cacodylate-buffered 1% osmium tetroxide, dehydrated in a graded ethanol series, transitioned to propylene oxide, and embedded in Epon 812-Araldite. Semithin sections (0.8 μm) were obtained using a Reichert UltracutE ultramicrotome, stained with gentian violet and basic fuchsin, observed under a Leica DM 6000B microscope and photographed with a digital camera.
ZO1 Immunofluorescence Analysis of Zebrafish Embryos
Control and MO-treated tg(fli1:EGFP) y1 embryos were fixed at 30 hpf in 4% paraformaldehyde for 2 hours at room temperature. Wholemount immunofluorescence analysis was performed as described 25 using a mouse anti-ZO1 antibody (Invitrogen) followed by Alexa Fluor 594 anti-mouse IgG (Invitrogen) and embryos were analysed by confocal laser microscopy.
zS1P 1 Transfection in Mammalian Cells and cAMP Assay
The polymerase chain reaction (PCR) fragment with the fulllength coding sequence of zS1P 1 was cloned from the total RNA isolated from zebrafish embryos at 24 hpf (primer set: forward, 5ʹ-TCCATGATGCAGTTTTTGGA-3ʹ; reverse, 5ʹ-AGTTCCATCCCTCCAGTTT-3ʹ) into the pCRII-TOPO vector (Invitrogen). Next, the zS1P 1 coding region was subcloned from pCRII-TOPO into the pcDNA5/FRT/TO vector (Invitrogen) using BamHI and XbaI (Fermentas Life Sciences, St. Leon-Rot, Germany). Chinese hamster ovary-FlpIn cells (Invitrogen) were maintained in Ham-F12 with L-glutamine, supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin, and 10% charcoalstripped fetal calf serum (Invitrogen). Ten μg of plasmid DNA were used for transfection into Chinese hamster ovary-FlpIn cells using Lipofectamine 2000 (Invitrogen). After 24 hours, transfected cells were washed with serum-free medium and serum starved for 16 hours. Next, transiently transfected cells were detached from the surface using cell dissociation buffer (Invitrogen), washed once with Hanks balanced salt solution, and resuspended in 5.0 mmol/L Hepes buffer, containing Hanks balanced salt solution with 0.05% fatty acid-free BSA (Sigma). Stimulation mixtures consisted of stimulation buffer with 3 μmol/L forskolin, 0.5 mmol/L 3-isobutyl-1-methylxanthine (IBMX) (both from Sigma) and the concentration response curve of the indicated compounds. Cells (2500 per well) were added to the stimulation mixtures in a 1:1 ratio in a 384-well Optiplate (Perkin-Elmer, Zaventem, Belgium) and stimulated for 30 minutes. The LANCE cAMP 384 kit (Perkin-Elmer) was used to determine the concentration of cAMP accumulated during stimulation according to the manufacturer's protocol in a total volume of 20 μL. Measurements were performed 3 hours after adding detection buffer and antibody mixture using a Wallac 1420 Victor 2 (PerkinElmer). Data are expressed as the potency of the indicated compound to inhibit forskolin-induced cAMP accumulation (calculated as pEC 50 value, here defined as the negative logarithm of the EC 50 value).
Quantitative RT-PCR Analysis
Total RNA was isolated from zebrafish embryos using Trizol reagent (Invitrogen). Approximately 2 μg of total RNA were retrotranscribed using M-MLV Reverse Transcriptase (Invitrogen). Quantitative real-time PCR (qRT-PCR) was performed with a Biorad iCycler iQ Real-Time PCR Detection System using iQ SYBR Green Supermix (Biorad, Hercules, CA) according to manufacturer's instructions. Primers sequence were as follows: EphB4 (forward: 5ʹ-GGGGCCTGCAGGAGAGACCA-3ʹ, reverse: 5ʹ-GATCCGCGCTCCTTCTCGCA-3ʹ);
VE-cadherin (forward: 5ʹ-TGACGAGGAGGGCGGAGGAG-3ʹ, reverse: 5ʹ-AGGTCCCACA CTGGGCCGAA-3ʹ); β-actin (forward: 5ʹ-CGAGCAGGAGATG GGAACC-3ʹ, reverse: 5ʹ-CAACGGAAACGCTCATTGC-3ʹ).
Samples were analyzed in triplicate, normalized against the threshold cycle (C t ) of β-actin, and expressed as changes with respect to the levels of the gene under investigation in control samples.
HUVEC Cultures
HUVECs were grown in M199 medium (Invitrogen) supplemented with 20% fetal calf serum (Invitrogen), endothelial cell growth factor (100 μg/mL, Sigma), and porcine heparin (100 μg/mL, Sigma). HUVECs were used at early passages (I-V) and grown on plastic surface coated with porcine gelatin (Sigma). When indicated, HUVECs were transfected with control-scrambled siRNA or with specific S1P 1 siRNAs (TAGCATTGTCAAGCTCCTAAA, S1P 1 siRNAa; and CTCGGTCTCTGACTACGTCAA, S1P 1 siRNAb; both from Qiagen, Chatsworth, CA) using the HiPerFect Transfection Reagent (Qiagen) according to the manufacturer's instructions. Transfection efficiency was equal to 70% to 80% as shown by transfection with a fluoresceinconjugated control siRNA.
Western Blot Analysis of HUVECs
HUVECs were incubated with 30-μmol/L W146 for 48 hours, and cells lysates were probed with anti-EPHB4 antibody in a Western blot (Santa Cruz Biotechnology). Uniform loading of the gels was assessed using anti-focal adhesion kinase antibodies. In the second set of experiments, S1P 1 siRNA-transfected HUVECs were analyzed 96 hours after transfection by Western blotting with anti-EPHB4 and anti-S1P 1 antibodies (Santa Cruz Biotechnology). The corresponding immunoreactive bands were quantified by computerized image analysis and data were normalized for the intensity of the control tubulin band in the same sample.
Immunofluorescence Analysis of HUVECs
Cells were seeded on gelatine-coated coverslips in complete cell culture medium and allowed to reach confluence. Then, confluent cells were incubated for 24 hours in the absence or in the presence of TNYL-RAW or SCR-WTL (both at 100 μmol/L), washed, fixed in 4% paraformaldehyde in PBS, permeabilized with 0.2% Triton-X100, and blocked with 10% BSA/0.1% Triton-X100 in PBS. Then, cells were incubated with the mouse anti-ZO1 antibody followed by incubation with Alexa Fluor 488 anti-mouse IgG (Invitrogen) and nuclear counterstained with 4ʹ,6-diamidino-2-phenylindole (DAPI). Then, cells were photographed using a LSM510 Meta confocal microscope equipped with a Plan-Apochromat ×63/1.4 NA oil objective.
Results
Vascular Expression of zS1P 1
The complete coding sequence of zS1P 1 (GenBank accession no. NM_131691) was cloned from the total RNA isolated from zebrafish embryos at 24 hpf. In keeping with previous observations, 13 zS1P 1 encodes for a putative 362 amino acid protein highly homologous to human and murine S1P 1 receptors (70% and 71% similarity, respectively). Accordingly, both the selective S1P 1 receptor agonists SEW2871 26 and CYM5442 17 and the nonselective S1P receptor agonists S1P, dhS1P, and synthetic FTY720-P 27 potently inhibit forskolin-induced cAMP accumulation in Chinese hamster ovary-FlpIn cells transiently transfected with the zS1P 1 cDNA with the following ranking order: FTY720-P>dhS1P≈S1P>CYM5442≈SEW2871 (Table) . Similar results were obtained for Chinese hamster ovary-FlpIn cells transiently transfected with the human S1P 1 cDNA (Table) , thus, confirming that zS1P 1 encodes for the bona fide zebrafish ortholog of the human S1P 1 gene.
On this basis, we analyzed the expression pattern of the zS1P 1 gene in zebrafish embryos by whole-mount ISH. In agreement with previous observations, 13 zS1P 1 expression is restricted to the diencephalon at early somitogenesis (data not shown) and is widespread in the brain and neural tube at subsequent stages of development ( Figure 1 ). Interestingly, whole-mount ISH showed also a transient but significant expression of zS1P 1 transcript in the axial vasculature of the trunk of zebrafish embryos. This vascular pattern expression occurs at 24 hpf ( Figure 1A and 1B), is maintained at 26 hpf ( Figure 1D and 1E), and decreases at 30 hpf ( Figure 1G and 1H), being lost at 48 hpf (data not shown). Analysis of the cross sections of the trunk of 24, 26, and 30 hpf embryos confirmed that, in addition to the neural tube, zS1P 1 marks the zS1P 1 indicates zebrafish ortholog of the endothelial sphingosine-1-phosphate receptor-1; dhS1P, dihydro-S1P.
*Chinese hamster ovary-FlpIn cells were transiently transfected with zebrafish zS1P 1 or human hS1P 1 receptor cDNAs and treated with the indicated receptor agonists.
† Data are expressed as the potency of the indicated compound to inhibit forskolin-induced cAMP accumulation (calculated as pEC 50 value, here defined as the negative logarithm of the EC 50 value) and represent the mean±SEM of 2 to 3 independent experiments. No effect was observed in mock-transfected cells (data not shown).
endothelium of the main medial dorsal aorta (DA) and posterior cardinal vein (PCV), as well as the basal aspect of the somites ( Figure 1C , 1F, and 1I).
Endothelial differentiation in zebrafish is under the control of the sonic hedgehog/vascular endothelial growth factor (shh/vegf) genetic pathway. 28 Endothelial expression of zS1P 1 in the axial vasculature of the trunk of 26 hpf embryos was abrogated by treatment with cyclopamine, a potent inhibitor of shh signaling 29 (data not shown) or after downregulation of vegf expression by antisense MO injection ( Figure 2) . Specificity of the effect was demonstrated by the lack of effect of both treatments on somitic and central nervous system expression of zS1P 1 , thus, indicating that endothelial zS1P 1 expression is under the control of the shh/vegf cascade.
30
MO Knockdown of zS1P 1 Function Results in Venous Vascular Barrier Defects
To assess the functional role of zS1P 1 in zebrafish vascular development, we used an antisense MO knockdown approach. 31 To this purpose, a MO was designed directed against the 5ʹ untranslated region spanning the zS1P 1 ATG start codon to inhibit protein translation (zS1P 1 -MO). Next, tg(fli1:EGFP) y1 transgenic zebrafish embryos in which EGFP expression is driven by the promoter of the pan-endothelial marker fli-1 were injected at the 1-to 4-cell stage with different doses of zS1P 1 -MO (ranging from 0.1-0.4 pmoles/ embryo) or of control std-MO and the development of EGFPlabeled blood vessels was directly observed in live embryos. Whole-mount microscopic analysis of 24-hpf embryos injected with 0.4 pmoles/embryo of zS1P 1 -MO revealed the presence of pericardial edema and enlargement of the PCV ( Figure 3C and 3D) whose altered structure was confirmed by the analysis of histological semithin cross sections of the trunk of zS1P 1 morphants (Figure 4) . At 2.5 days postfertilization (dpf), intersomitic vessels of all zS1P 1 -MO-injected embryos (n=181) appear slightly thinner than in control Std-MOinjected embryos ( Figure 3J ). Also, zS1P 1 downregulation was associated with minor defects in the development of the duct of Cuvier and of the subintestinal vein basket in all mophants ( Figure 3K and 3L ). In keeping with the modest impact of zS1P 1 downregulation on blood vessel development, no differences in the expression of shh, vegf, kdr, and fli-1 genes were observed in zS1P 1 -MO-injected versus Std-MO-injected embryos (data not shown). These data support previous observations in S1P 1 -null mice indicating that this S1P receptor is not essential for vasculogenic and angiogenic events y1 embryos at 2.5 days postfertilization (dpf). Trunk and Duct of Cuvier regions highlighted by yellow and red boxes, respectively, are shown at higher magnification in (G), (H), (J), and (K); white arrowheads point to thinner intersomitic vessels (J) and to poorly developed Duct of Cuvier (K) in zS1P 1 morphants. I and L, Alkaline phosphatase staining of 3-dpf embryos revealed alterations of subintestinal vessel organization in zS1P 1 morphants (L). M and N, zS1P 1 knockdown causes absence of blood circulation as shown by microangiography performed at 50 hpf. O and P, Morphological appearance of control and zS1P 1 morphant larvae at 6 dpf; note the generalized edema in zS1P 1 morphants (P). Q, Dose-dependent effects of zS1P 1 knockdown: white bars, pericardial edema; black bars, absence of blood circulation; gray bars, late generalized edema (each point is the mean±SD of 97-181 embryos per group).
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during embryogenesis. 5 However, despite minor alterations in vascular development, the presence of a beating heart with no major developmental defects ( Figure 5 ) and of a patent lumen in both DA and PCV cross sections (Figure 4) , zS1P 1 -MOinjected embryos showed no apparent blood circulation, as confirmed by the absence of tetramethylrhodamine isothiocyanate-dextran perfusible vessels at 50 hpf ( Figure  3N ). Of note, 6 dpf zS1P 1 -MO-injected embryos showed a remarkable generalized edema never observed in control embryos ( Figure 3P ). The incidence of phenotypic alterations (early pericardial edema, lack of blood circulation, and late generalized edema) was directly related to the dose of injected zS1P 1 -MO, 100% of the embryos showing all these defects when injected with 0.4 pmoles/embryo ( Figure 3Q ). The appearance of the generalized edema, already evident at 4 dpf, was fully prevented when zS1P 1 morphants were grown in fish water containing 250 mmol/L D-mannitol. Nevertheless, blood circulation was not restored (data not shown).
To confirm the specificity of the vascular and circulatory defects in zS1P 1 morphants, zS1P 1 -MO was coinjected with a MO-resistant form of the human S1P 1 mRNA. In 2 independent experiments, analysis of the embryos at 30 hpf showed the ability of the human transcript to rescue the zS1P 1 -knockdown phenotype, as assessed by the presence of normal blood flow in 76% of rescued embryos when compared with 36% of zS1P 1 morphants (P<0.001; Fisher exact test; Figure 6A ). Also, analysis of the embryos at 6 dpf showed the ability of the human transcript to rescue the generalized edema observed in zS1P 1 morphants. In fact, only 34% of zS1P 1 morphants coinjected with the human S1P 1 mRNA developed generalized edema when compared with 57% of zS1P 1 morphants (P<0.001; Fisher exact test; Figure 6B ). S1P 1 receptor and its ligand S1P play an important role in the control of vascular barrier by affecting endothelial cell-cell junctions, 15 including the expression of the adherens junction component VE-cadherin. 10 The phenotype observed in zS1P 1 morphants prompted us to assess the possibility that zS1P 1 may control endothelial barrier integrity in zebrafish. On this basis, the effect of zS1P 1 downregulation on the organization of endothelial cell-cell junctions was investigated by whole-mount ISH of VE-cadherin 32 expression in the axial vasculature of the trunk and by immunofluorescence analysis of ZO1, a tight junctionassociated protein functionally critical in regulating S1P-mediated endothelial barrier integrity. 33 As shown in Figure  7B , zS1P 1 knockdown caused the selective downregulation of VE-cadherin in the PCV but not in the DA of zS1P 1 morphants. In keeping with the ISH data, the RT-PCR analysis showed a decrease of steady state VE-cadherin mRNA levels in zS1P 1 morphants when compared with control embryos (31%±12%, average of the 2 independent experiments). Also, confocal microscopy analysis of the vasculature of the trunk of control and zS1P 1 morphants at 30 hpf revealed a complete disorganization of the ZO1 + endothelial junctions in the PCV of all the zS1P 1 morphants examined (n=5) ( Figure 7D) . Instead, no effect on ZO1 immunolocalization was observed in the DA of zS1P 1 morphants ( Figure 7D ) and in both axial vessels of std-MO-injected embryos ( Figure 7C ). Together, the data indicate a nonredundant Figure 6 . Human hS1P 1 overexpression rescues vascular defects in the zebrafish ortholog of the endothelial sphingosine-1-phosphate receptor-1 (zS1P 1 ) morphants. zS1P 1 morphants were injected with hS1P 1 mRNA and lack of blood flow (A) and generalized edema (B) were analyzed at 30 hours postfertilization and 6 days postfertilization (dpf), respectively. hS1P 1 
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vascular function for zS1P 1 that affects venous endothelial cell-cell barrier in zebrafish.
Downregulation of Venous Endothelial EphB4a Expression in zS1P 1 Morphants
The selective effect of zS1P 1 knockdown on PCV structure, VE-cadherin expression, and ZO1 organization prompted us to investigate the expression of arterial and venous markers in the axial vessels of the trunk in zS1P 1 -MO-injected embryos.
As shown in Figure 8 , zS1P 1 downregulation does not affect the expression of the specific arterial markers ephrinB2 30 and crlr 34 in the DA of zS1P 1 morphants. Also, zS1P 1 -MO injection does not alter the expression of the venous markers flt4 35 and dab2 36 in the PCV. Thus, in keeping with previous observations in S1P 1 null mice, 5 the data indicate that zS1P 1 knockdown does not affect arterial/venous differentiation of endothelial cells in zebrafish. However, zS1P 1 downregulation caused the loss of the expression of the Eph receptor EphB4a in the PCV of zS1P 1 -MO-injected embryos ( Figure 8J ), as confirmed by the decrease of steady state EphB4a mRNA levels in zS1P 1 -null embryos when compared with controls (38%±9%, average of the 2 independent quantitative RT-PCR experiments). Of note, zS1P 1 downregulation did not affect the expression of EphB4a in the gut of zebrafish embryos, thus demonstrating the specificity of the effect of zS1P 1 -MO on EphB4a expression in PCV (asterisk in Figure 8I and 8J).
The loss of EphB4a and VE-cadherin expression in venous endothelium of zS1P 1 morphants (72% and 75% of zS1P 1 morphants, respectively) was significantly reduced to 24% and 25% for the 2 genes in embryos coinjected with the human S1P 1 mRNA (Figure 6C ), thus confirming the specificity of the effect (P<0.001, Fisher exact test). Also, heart beating arrest after treatment with a high dose of ethyl-m-aminobenzoate (tricaine) did not affect EphB4a and VE-cadherin expression in zebrafish embryos (n=22), thus, indicating that the observed downregulation of these genes in zS1P 1 morphants is not the direct consequence of the lack of blood flow ( Figure  9 ). Finally, coinjection of the human S1P 1 mRNA fully rescued ZO1 organization in the PCV of zS1P 1 morphants (data not shown). These observations point to a role for S1P 1 receptor in the control of venous endothelial cell functions and gene expression in zebrafish.
VE-cadherin Acts Upstream of EphB4a in Modulating Venous Vascular Barrier Organization
Previous observations had demonstrated a tight relationship between the expression of the members of the cadherin family of adhesion molecules and Eph receptors in epithelial cells. 37 On this basis, we addressed the possibility that the venous endothelial barrier defects in zebrafish embryos lacking zS1P 1 activity might be the consequence of defects in a putative zS1P 1 /VE-cadherin/EphB4a pathway.
To assess this hypothesis, we investigated the effect of VE-cadherin downregulation on EphB4a expression and vascular integrity in zebrafish morphants. 32 As shown in Figure 10 , embryos injected with VE-cadherin-MO (1.0 pmoles/embryo) showed downregulation of EphB4a expression (24/24 embryos), pericardial edema and lack of blood circulation (28/30 embryos, data not shown), and late generalized edema (19/22 embryos) with no changes in vascular zS1P 1 expression (13/13 embryos). Also, VE-cadherin morphants revealed a complete disorganization of the ZO1 + endothelial junctions in PCV and DA of all the embryos examined ( Figure 10H ). These data extend previous observations about the role of VE-cadherin on vascular stability in zebrafish. 32, 38 On this basis, to assess whether exogenous VE-cadherin is sufficient to rescue EphB4a expression and vascular integrity in the absence of zS1P 1 activity, zS1P 1 Figure 8 . The zebrafish ortholog of the endothelial sphingosine-1-phosphate receptor-1 (zS1P 1 ) knockdown causes EphB4a downregulation in posterior cardinal vein (PCV). Standard-MO (std-MO)-and zS1P 1 -MO-injected embryos were analyzed at 28 hours postfertilization for the expression of the indicated markers by in situ hybridization (lateral view of the trunk region; dorsal aorta (DA), white arrow; PCV, yellow arrow). zS1P 1 morphants were characterized by the lack of expression of EphB4a in the PCV (J; 43/60 embryos examined). In contrast, arterial markers ephrinB2 (B) and crlr (D) and venous markers flt4 (F) and dab2 (H) were expressed in 9/10, 9/12, 11/12, and 14/18 zS1P 1 morphants, respectively. All genes were instead normally expressed in all control embryos examined (A, C, E, G, and I; n=15-30). Note that EphB4a expression, downregulated in the PCV, is maintained in the gut of all the zS1P 1 morphants (asterisk in I and J). Transverse sections highlighted as vertical black bars confirm EphB4a downregulation in the PCV of zS1P 1 morphants when compared with controls (insets in I and J).
morphants were injected with the mRNA encoding for murine VE-cadherin. 32 As shown in Figure 11B and 11C, the loss of EphB4a expression in venous endothelium of zS1P 1 morphants was significantly reduced in embryos coinjected with the murine VE-cadherin mRNA (78% versus 41% of morphants, respectively; P<0.001, Fisher exact test). Also, injection of VE-cadherin mRNA caused a significant decrease in the number of zS1P 1 morphants showing early pericardial edema, lack of blood circulation, and late generalized edema ( Figure  11A ). Accordingly, VE-cadherin mRNA overexpression rescued the organization of ZO1 + endothelial junctions in the PCV of zS1P 1 morphants ( Figure 11E ). At variance, no rescue was observed after injection of zS1P 1 morphants with VEGF-A mRNA, thus confirming the specificity of the effect (data not shown). These results suggest that the loss of EphB4a expression in zS1P 1 morphants is a result of the VE-cadherin downregulation in PCV endothelium downstream of zS1P 1 , pointing to the existence of a zS1P 1 /VE-cadherin/EphB4a pathway modulating venous vascular barrier organization in zebrafish embryo.
EPHB4 Controls Barrier Integrity in HUVECs
The segregation of distinct arterial and venous vessels is disrupted by EphB4a knockdown in zebrafish, 39 hampering the possibility to use EphB4a morphants to directly assess the role of this receptor in PCV integrity. Also, EphB4a overexpression severely affects the general development of S1P 1 morphants (data not shown), forbidding phenotypic rescue experiments in these embryos.
To overcome these limitations and to confirm that a S1P/ Eph receptor cross talk may modulate intercellular contacts also in mammalian venous endothelium, we took advantage of HUVECs that express both S1P 1 40 and the Eph receptor EPHB4. 19 As anticipated, a 1-hour pretreatment of confluent HUVECs with 30 μmol/L of the selective S1P 1 antagonist
W146
15 prevents ZO1 + intercellular junction assembly triggered by a 2-hour treatment with 62.5 nmol/L S1P (data not shown) and causes a potent inhibition of EPHB4 expression in both control and S1P-treated HUVECs as assessed by quantitative RT-PCR (87%±2% and 95%±1% inhibition, respectively; n=2). Accordingly, W146 treatment induces a significant inhibition of the levels of EPHB4 receptor protein in these cells ( Figure 12A) .
Only a limited inhibition of EPHB4 protein levels was observed after transfection with either 1 of the 2 different S1P 1 siRNAs, each causing a partial downregulation of S1P 1 expression ( Figure 12B) . However, the simultaneous H) . In contrast, normally organized ZO1 + junctions were observed in both axial vessels of control embryos (G). VEcadherin downregulation does not affect zS1P 1 expression in DA and PCV (E and F).
transfection with both S1P 1 siRNAs allowed a more significant downregulation of S1P 1 receptor and resulted in a remarkable decrease of EPHB4 protein levels ( Figure 12B) , with ≈25% to 30% of the receptor levels detected in cells transfected with the scrambled siRNA as assessed by computerized image analysis of the immunoreactive bands ( Figure 12C ). Thus, in agreement with the data obtained with zS1P 1 morphants, these results indicate that the suppression of S1P 1 receptor expression (by siRNA transfection) or activity (by W146 treatment) induces a significant downregulation of EPHB4 in HUVEC.
On this basis, we investigated the effect of the selective EPHB4 receptor antagonist TNYL-RAW peptide and of the control-scrambled peptide SCR-WTL 18, 19 on ZO1 + intercellular contact organization in HUVECs. Similar to W146 (data not shown), TNYL-RAW inhibited ZO1 organization in cellcell junctions of confluent HUVEC monolayers maintained in serum-containing cell culture medium, whereas no effect was exerted by the control-scrambled peptide SCR-WTL ( Figure 12D ). In keeping with our observations in zebrafish embryos, these data support a direct functional role for the Eph receptor EPHB4 in mediating S1P 1 -dependent organization of ZO1 + intercellular junctions in venous endothelium.
Discussion
In this study, we report the characterization and functional analysis of S1P 1 , a major endothelial S1P receptor, in the development of vascular system in zebrafish embryo. Here we show that S1P 1 plays a nonredundant role in the regulation of endothelial barrier in zebrafish via a novel S1P 1 /VEcadherin/EphB4a genetic pathway that controls venous vascular integrity.
In agreement with previous observations, 13 pharmacological characterization based on the effect of nonselective and selective S1P 1 receptor agonists on forskolin-induced cAMP accumulation demonstrates that the binding properties of the cloned zS1P 1 receptor expressed in mammalian cells are similar to those shown by its human counterpart, thus confirming that zS1P 1 encodes for the bona fide zebrafish ortholog of the human S1P 1 gene. Consistent with a vascular pattern of expression of S1P 1 in mouse embryo, 5 zS1P 1 is expressed in the axial vasculature of the trunk of zebrafish embryos, whole-mount ISH showing that zS1P 1 transiently marks the endothelium of DA and PCV at 24 to 30 hpf, being lost at 48 hpf. The shh signaling inhibitor cyclopamine or vegf antisense MO both abrogate expression of zS1P 1 in the axial vasculature of the trunk, thus indicating that endothelial zS1P 1 expression is under the control of the endothelial differentiation shh/vegf genetic pathway. 30 These data extend previous observations about the ability of vascular endothelial growth factor to upregulate S1P 1 expression in mammalian endothelium. 41 Here, we show that zS1P 1 morphants are characterized by minor defects in the vascular development of intersomitic vessels, duct of Cuvier, and subintestinal vein basket. This was paralleled by early pericardial edema, lack of blood circulation, alterations of PCV structure, and a dramatic late generalized edema. Interestingly, several of these phenotypic features were observed also in S1P 1 null mice, 5 as well as in VE-cadherin zebrafish morphants (C. Tobia, our unpublished observations, 2010). 32 However, S1P 1 -null mice exhibit massive embryonic hemorrhage and deficient smooth muscle cell/pericyte recruitment in embryonic vasculature, 5 defects that were not observed in zS1P 1 morphants. These species differences may be, at least in part, a result of the fact that zebrafish is characterized by a delay in smooth muscle cell/ pericyte maturation with a very limited PCV coverage with respect to mammals. 42 Indeed, transgelin-positive mural cells are not yet detectable in PCV of zebrafish embryos at 80 hpf or 120 hpf, 42 when the vascular defects in zS1P 1 morphants are already established.
Lack of blood circulation and pericardial edema have been observed also in S1P 2 receptor mil zebrafish mutants as a consequence of profound defects in heart organogenesis.
14 At variance with mil mutants, we did not observe major defects in the developing heart of the zS1P 1 morphants, as indicated by the normal pattern of expression of the cardiac myogenesis genes ventricular myosin heavy chain, atrial myosin heavy chain, and cardiac myosin light chain 2 (see Figure 5) , demonstrating that the 2 S1P receptors play different roles in zebrafish development.
Edema formation may result from cardiovascular, lymphatic vascular or excretory system defects. To this respect, zS1P 1 morphants showed an apparently normal lymphatic thoracic duct at 4 dpf (C. Tobia, unpublished observations, 2010). Also, high molecular weight proteins (≥80 000) were present in the extravascular transudate we collected from edematous zS1P 1 morphants at 6 dpf but not in the transudate collected from prox-1 morphants showing lack of lymphatic vessel development 43 as observed by SDS-PAGE (C. Tobia, unpublished observations, 2010). Thus, even though the effect of zS1P 1 knowdown on cardiac, lymphatic and excretory system development and function will deserve further investigation, our observations suggest that alterations of endothelial barrier integrity may contribute, at least in part, to the edematous phenotype observed in zS1P 1 morphants.
Actually, in keeping with a role for S1P 1 in vascular barrier integrity, zS1P 1 morphants showed significant alterations of vessel morphology, downregulation of VE-cadherin expression, and ZO1 disorganization in PCV but not in DA. It must be pointed out that zS1P 1 knockdown did not affect arterial/venous differentiation of endothelial cells in zebrafish. Indeed, zS1P 1 morphants did not show any change in the levels of expression of shh, vegf, kdr, and fli-1, as well as of the arterial markers ephrinB2 30 and crlr 34 and of the venous markers flt4 35 and dab2, 36 thus confirming previous observations in S1P 1 −/− mice. 5 Nevertheless, the expression of the Eph receptor EphB4a was significantly downregulated in zS1P 1 -MO-injected embryos. To this respect, it is interesting to note that EphB4a knockdown after MO injection at 1-to 4-cell stage has a dramatic impact on early vascular development and arterial/venous segregation in zebrafish. 39 In contrast, as stated above, EphB4a downregulation in zS1P 1 morphants, which occurs at 28 hpf in the already differentiated PCV, is paralleled only by minor defects in late vascular development, mostly affecting venous microcirculation (ie, the duct of Cuvier and the subintestinal vein basket) with no apparent effect on arterial/venous differentiation. Taken together, these data suggest that EphB4a may play a dual role in the circulatory system of zebrafish: an earlier effect on arterial/venous differentiation and a later effect on venous vascular integrity. In keeping with this hypothesis, EphB4a has been shown to regulate venous remodelling in the adult murine vasculature. Eph receptors have been implicated in the permeability of epithelial and endothelial barriers 45 and EphA receptors have been suggested to act downstream of E-cadherin to mediate epithelial cell-to-cell contacts. 37 Our data strongly suggest that a cadherin/Eph receptor cross talk may exist also in the endothelial cells, genetic VE-cadherin/EphB4a interactions mediating venous vascular integrity downstream of S1P 1 . Several experimental evidences support this hypothesis.
(1) The S1P/S1P 1 receptor system modulates VE-cadherin expression and the localization of this adherens junction component at intercellular junctions in mammalian endothelium. 10 18, 19 prevents ZO1 + intercellular contact organization in the same cells. Together, the data point to the existence of a S1P 1 /VE-cadherin/EphB4a genetic pathway modulating vascular barrier organization in venous endothelium.
At present, the molecular mechanism(s) orchestrating this genetic pathway remain unravelled. To this respect, the capacity of zS1P 1 in modulating intercellular barrier appears to be restricted to venous endothelium. Indeed, even though zS1P 1 receptor is expressed in both DA and PCV endothelial cells, its knockdown results in VE-cadherin downregulation with consequent alterations of vessel morphology and disorganization of ZO1 + endothelial junctions only in PCV, with no apparent alterations of arterial endothelium. This indicates that VE-cadherin expression and endothelial barrier integrity are controlled by different mechanisms in venous and arterial endothelium of zebrafish embryo.
Endothelium demonstrates remarkable heterogeneity in structure and function. 47 Within the microvasculature, junctions are tighter in arterioles compared with capillaries and are quite loose in venules, likely reflecting the role of postcapillary venules in mediating inflammation-induced extravasation of leukocytes and plasma constituents. 48 Accordingly, differences in the expression of adherens junctional proteins have been reported in arterial versus venous endothelial cells. 49, 50 Several transcription factors, including members of the E-26 and Twist/Slug/Snail families, and Wnt/β-catenin signaling regulate VE-cadherin expression. 51 Further experiments are required to elucidate the transcriptional and signaling mechanisms responsible for the observed modulation of VE-cadherin expression in human 46 and zebrafish (present work) endothelium by S1P 1 knockdown and the molecular bases responsible for the different responses of venous and arterial vascular beds to zS1P 1 downregulation in zebrafish embryo.
Alterations of the endothelial barrier integrity may occur in different pathological conditions, including acute respiratory distress syndrome in the lung, ischemia-reperfusion stresses in the kidney and myocardium, and experimental autoimmune encephalomyelitis in the brain. In all these conditions, S1P receptor activation may favour vascular integrity, synthetic chemical agonists/antagonists of S1P receptors representing therapeutic modulators of the endothelial barrier. 4 Zebrafish is suitable for high-throughput screening of chemical compounds using robotic platforms. 52, 53 Also, zebrafish has been proposed as a suitable animal model of human vascular malformation disorders. 6 Our findings indicate that this animal model may provide useful information about the molecular mechanisms regulating vascular barrier integrity and may be used for the screening of novel endothelial barrier-targeting therapeutics.
